-
Mashup Score: 0
ALK Positive has established a 12-member scientific advisory board that will guide the patient-driven organization’s research and strategic priorities, its leadership announced.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Preliminary Data Presented on Epoetin Alfa Dose Escalation With Stable Hydroxyurea for SCD Anemia | Docwire News - 10 day(s) ago
Preliminary efficacy and safety findings from a multicenter, open-label, phase Ib/II prospective study have been encouraging.
Source: docwirenews.comCategories: General Medicine News, Oncologists1Tweet-
An ongoing prospective study by @CmulNigeria, @PittTweet has promising initial efficacy, safety data for dose escalation of #epoetinalfa plus stable #hydroxyurea for tx of #anemia in #sicklecelldisease. #SCD, #ASH24, #Heme https://t.co/hfHRJfgfFO
-
-
Mashup Score: 0Association Between Gout and Kidney Stones | Docwire News - 10 day(s) ago
A study examined the relationship between gout and kidney stones using NHANES data.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Researchers used NHANES data to investigate a potential association between gout and kidney stones. #nephrology #nephtwitter #kidneystones #gout https://t.co/Jolcm6Hw0v https://t.co/xZniKMa7jA
-
-
Mashup Score: 7The Future of Surgery for Stage IV Lung Cancer: Dr. Antonoff Shares Hopes, Insights | Docwire News - 10 day(s) ago
Mara B. Antonoff, MD, FACS, of the University of Texas MD Anderson Cancer Center, discusses what could be on the horizon for surgery in stage IV lung cancer at STS 2025.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 What does the future hold for surgery in stage IV lung cancer? 💡 In this new interview, @maraantonoff discusses what she hopes to see on the horizon and shares insights from the #STS2025 session on the topic. ➡️ Watch: https://t.co/YWwRCJ9iXP @STS_CTsurgery #lcsm #STS25 https://t.co/sjYQlYEBb0
-
-
Mashup Score: 0Phase 3 HARMONi-6/AK112-306 Trial of Ivonescimab Plus Chemotherapy for NSCLC Completes Enrollment | Docwire News - 11 day(s) ago
The trial is comparing ivonescimab plus platinum-based chemotherapy to tislelizumab plus platinum-based chemotherapy as first-line therapy for squamous non–small cell lung cancer.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 Patient enrollment has been completed in the phase 3 HARMONi-6/AK112-306 trial, according to an announcement from Akeso Biopharma. ➡️ Learn more about the study: https://t.co/243df3VyHx #NSCLC #lcsm https://t.co/1QaOjt16JU
-
-
Mashup Score: 0Transplantation of Kidneys From Donors With HIV to Recipients With HIV | Docwire News - 11 day(s) ago
A study examined the safety and noninferiority of kidney transplantation from donors with human immunodeficiency virus (HIV) to recipients with HIV.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
How safe is kidney transplantation from donors with HIV to recipients with HIV? #nephrology #nephtwitter #kidneytransplantation #hiv https://t.co/H9lsyb3PSg https://t.co/nAOvp57vG8
-
-
Mashup Score: 0Liso-Cel in MZL, Follicular Lymphoma Produces Favorable Overall, Complete Response Rates | Docwire News - 11 day(s) ago
In the phase II TRANSCEND FL trial the CAR T-cell therapy has shown good efficacy and manageable safety in MZL and FL.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
From the #TRANSCENDFL phase II trial of #lisocabtagenemaraleucel: #Lisocel is showing favorable response rate performance in #marginalzonelymphoma, #follicularlymphoma, with manageable safety. #MZL, #Heme https://t.co/Wo0c5EFeWg
-
-
Mashup Score: 5
At ASCO GI 2025, Boris Pasche, MD, PhD, of Karmanos Cancer Institute gave an overview of the TheraBionic P1 device and how it works as a systemic targeted therapy for advanced HCC.
Source: docwirenews.comCategories: General Medicine News, UrologyTweet-
🥄 At @ASCO #GI25, Boris Pasche, MD, PhD, of @karmanoscancer gave an overview of the TheraBionic P1 device and how it works as a systemic targeted therapy for advanced hepatocellular carcinoma. 📺 Learn more about how the device works: https://t.co/dbwDBbxgD3 https://t.co/H8PT6VcRZF
-
-
Mashup Score: 2
HistoTME, a novel deep learning approach, can characterize the tumor microenvironment molecular composition and predict responses to immune checkpoint inhibitors in NSCLC.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 A novel deep learning approach may be an effective way to characterize the TME & predict responses to ICIs in NSCLC, according to research presented at #SITC24 by a team from @theNCI. ➡️ Learn more: https://t.co/LqNptHvtKG #lcsm #LungCancer #NSCLC https://t.co/GFHInDwBXM
-
-
Mashup Score: 1New Lentiviral Vector–Transduced Hematopoietic Cell Therapy Shows Favorable Effect in Hemophilia A | Docwire News - 12 day(s) ago
A study cohort with severe disease over a median follow-up of 14 months had an annualized bleeding rate of zero.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Progress in #genetherapy for severe #hemophilia A: In a study, autologous CD34-positive hematopoietic stem cells transduced with #CD68ET3LV #lentiviralvector had favorable effects in factor VIII expression, annualized bleeding rate. #Heme https://t.co/Y7viBC3up8
-
⭐ Today, @ALKPositiveinc announced the formation of its Scientific Advisory Board! 🗨️ Don't miss this insightful interview about the new board with ALK Positive President Kirk Smith & Dr. Ken Culver, Director of Research & Clinical Affairs! ➡️ Watch: https://t.co/FV3wWGEKnh https://t.co/ej0pyLOEkY